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1. Introduction 
It is generally believed that the coronary plaques with lipid-laden thin fibrous cap and a 
large lipid core beneath are vulnerable and imaging methods such as intravascular 
ultrasonography1, optical coherence tomography2, and angioscopy3-5 are clinically employed 
to detect this type of plaques. However, the coronary plaques that have a thin cap composed 
of tight calcium layers are frequently observed during post-mortem examinations3. 
Moreover, plaques wherein the deposition of lipids and macrophages is confined to just the 
superficial layers and in which a lipid core is not present also exist3,6. These evidences 
indicate the necessity of detailed molecular characterization for the detection of vulnerable 
plaques.   
Oxidized low-density lipoprotein (ox-LDL) plays an important role in the initiation, 
progression and destabilization of atherosclerotic plaques by inducing the proliferation and 
elongation of survival of macrophages7,8.  
Normal collagen fibers (CFs) that contain collagen-I in abundance protect the coronary 
plaques against mechanical stress. During plaque growth, collagen-I is replaced by 
collagen-III, -IV and/or -V9-11, and CFs are degenerated, disrupted, and finally destroyed 
by matrix metalloproteinases released by macrophages12. During this process, 
macrophages accumulate lipids such as cholesteryl esters (CEs) and ox-LDL13,14 and 
become foam cells while simultaneously producing ceramide within themselves15; their 
death results in formation of the lipid core. Therefore, demonstrating the lack of collagen-I 
which is mainly contained in normal CFs, deposition of lipids and existence of ox-LDL 
and the substances that comprising ox-LDL is an essential requisite for the detection of 
vulnerable plaques, but in-vivo clinical tools to visualize them in the coronary plaques are 
lacking.  
Structurally, ox-LDL is composed of cortex and core. The cortex is composed of 
lysophosphatidylcholine (LPC), free cholesterol (C) and Shiff base derived by oxidation 
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from apolipoprotein B (apoB), and the core is composed of triglyceride (TG), cholesteryl 
esters (CEs), and proteins (Figure 1).  
High-density lipoprotein (HDL) is composed of the same substances except Apo B, and 
plays a key role in reverse cholesterol transport but also stimulates prostacyclin release, 
enhances endothelial repair, inhibits monocyte recruitment into the arterial wall, and 
inhibits progression of and enhances regression of atherosclerosis16, 17. 
LPC itself is a pro-inflammatory substance, and plays a critical role in the atherogenic 
activity of ox-LDL. This substance is generated by lipoprotein-associated phospholipase A2 
18; induces vascular endothelial cell dysfunction19; causes endothelial cell apoptosis by DNA 
fragmentation20; stimulates adhesion and activation of lymphocytes and initiates chemotaxis 
of macrophages21; causes transformation of vascular smooth muscle cells that is 
characteristic of atherosclerosis.  
Apolipoprotein B-100 (apo B-100) is a major protein of low density lipoprotein (LDL)22. 
Serum Apo B-100 is elevated in patients with type 2 diabetes mellitus23 as well as in those 
with coronary artery disease24. Apo B-100 and apo B-100/apo A-1 ratio predict not only 
coronary artery disease25 but also other cardiovascular disease26, and metabolic syndrome27. 
Medical treatments have been directed to lower Apo B-10028.  
TG is also considered an important risk of cardiovascular disease, but lowering TG levels 
remains difficult to achieve29, 30. 
Although these substances in serum are measureable, measurement of these substances in 
the atherosclerotic plaques is difficult. If they become visible in patients in-vivo, initiation, 
progression and destabilization, and the effects of medical and interventional therapies on 
atherosclerotic plaques can be objectively evaluated.  
Based upon the knowledge about the pathophysiology of atherosclerosis, in-vitro and in-vivo 
animal studies and clinical trials have been performed using different tracers for plaque 
imaging studies, including radioactive-labelled lipoproteins, components of the coagulation 
system, cytokines, mediators of the metalloproteinase system, cell adhesion receptors, and 
even whole cells, or antibodies of the substances composing atherosclerotic plaques. 
However the majority of them are still not applicable clinically. 
Spectroscopy has been attempted intensively for molecular imaging of lipids within the 
atherosclerotic lesions in-vitro31,32. However, its clinical application started only recently33. 
Also, magnetic resonance imaging or computed tomography has been attempted for lipid 
imaging, however their clinical application is yet not established34,35. 
Although invasive, angioscopy is a clinically established high resolution technique, which 
enables direct, colored and three-dimensional imaging of the coronary arterial wall. 
Recently, fluorescent angioscopy, both color and near-infrared, was developed and is used 
for molecular imaging of the substances within the human coronary plaques not only in-
vitro36-39 but also in patients in-vivo36,37. 
The present article reviews recent advances in molecular imaging of the substances 
comprising atherosclerotic coronary plaques by fluorescent angioscopy.  
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TG: triglyceride. apo B: apolipoprotein B . PC: phosphatidylcholine. LPC: lysophosphatidylcholine. 
Fig 1. Schematic Representation of Structure of Low-density Lipoprotein (LDL) and 
Oxidized Low-density Lipoprotein (Ox-LDL). 
2. Fluorescent angioscopy system 
a. Color fluorescent angioscopy 
The color fluorescent angioscopy (CFA) system is composed of a fluorescence-excitation 
unit, an angioscope, a fluorescence-emission unit and a camera. The fluorescence-excitation 
unit is composed of a mercury-xenon lamp and seven sets of band-pass filter (BPF) discs, 
exchangeable by rotation for selection of the desired wave length of light ranging from 320- 
to 760-nm. The remaining single disc, which did not have any filter, was used to  irradiate 
white light for carrying out conventional angioscopy.  The angioscope (modified VecMover, 
Clinical Supply Co, Gifu, Japan) was composed of a 2.5-F fiberscope which contained 6000 
quartz fibers for the image guide and 300 quartz fibers for the light guide. This fiberscope 
was incorporated in a 5-F guiding balloon catheter and was steerable along a 0.014-inch 
guide wire; it also enabled observation of a coronary segment up to 7 cm in length by a 
single saline flush. This angioscope was approved for clinical use by the Japanese Ministry 
of Health and Labor and Welfare, and is widely used clinically in Japan.  
The fluorescence-emission unit is composed of seven sets of dichroic membrane (DM) and 7 
sets of band-absorption filter (BAF) discs which receive light ranging from 360- to 880-nm 
and is connected to a 3CCD digital camera (C7780, Hamamatsu Photonics, Hamamatsu). 
The obtained images are displayed on a computer screen through a camera controller 
(C7780, Hamamatsu Photonics, Hamamatsu). 
To observe the vascular lumen, the light and image guides are connected to the excitation 
and emission units, respectively. After selecting the desired BPF and BAF, the light is 
irradiated through the BPF and the light guide toward the target. A pair of BPF of 345±15 
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nm and BAF of 420 nm (“A” imaging), and another pair of 470±20 nm BPF and BAF of 515 nm 
(“B” imaging) are usually used for imaging The evoked fluorescence is received by the digital 
camera through the DM and BAF for successive three-dimensional imaging at an adequate 
time-interval from 0.01 to 1 s. The details of this CFA system are described elsewhere.41  
The intensity of the fluorescence images is arbitrarily defined as strong, weak and absent 
when the exposure-time required for imaging is within 0.5, more than 0.5 and within 1 and 
more than 1 s, respectively (Figure 2).                                                                
 
Cited from Ref. 41, with permission. 
Fig. 2. Schematic Representation of A Fluorescent Angioscopy System 
b. Near-infrared fluorescent angioscopy (NIRFA) 
For NIRFA, the BPF and BAF of the angioscopy system used for color fluorescent 
angioscopy system are replaced by a 710±25 nm BPF disc and 780-nm BAF disc by rotation, 
respectively, and color CCD camera is replaced by an intensified CCD camera (C3505, 
Hamamatsu Photonics)37. 
3. Color fluorescence of major substances that comprising atherosclerotic 
plaques examined by fluorescent microscopy  
a. Autofluorescence at “A”-imaging 
Among the major substances that constitute atherosclerotic plaques, collagen-I and -IV 
exhibit blue and light blue autofluorescence, respectively whereas collagen-III and -V did 
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not. Blue or light blue auto-fluorescence was not exhibited by other substances. Calcium 
phosphate, ceramide, and β -carotene which co-exists with lipid in the vascular wall, 
exhibited white, purple and orange auto-fluorescence, respectively (Figure. 3; Table 1) 
In the presence of β-carotene, collagen-I and -IV exhibited green fluorescence, collagen-III 
and -V showed white fluorescence, cholesterol (C) exhibited yellow fluorescence and 
cholesteryl esters (CEs) showed orange fluorescence (Figure 3; Table 1). 
 
 
 
 
From A to D: “A”-imaging of and E to H: “B”-imaging of collagens-I, -III, -IV and -V, respectively. By 
“A”-imaging, blue fluorescence was seen in collagen-I, no fluorescence in collagen-III, light blue 
fluorescence in collagen-IV and no fluorescence in collagen-V.  I: β-carotene (10-5 M) showing orange in 
fluorescence color by “A”-imaging. J: mixture of collagen-I and β-carotene showing green in 
fluorescent color by “A”-imaging. K: mixture of collagen-III and β-carotene showing white-to-light 
blue in fluorescence by “A”-imaging. Horizontal bar of each panel: 100μm. cited from Ref. 36, with 
permission. 
Fig. 3. Fluorescence of Collagen Subtypes Visualized by “A”- and “B”-Imagings of Color 
Fluorescent Microscopy (CFM) Before and After Mixing with β-Carotene. 
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AF: autofluorescence. EB: Evans blue. TB: Trypan blue. NB: Nile blue. Ho: Homidium chloride. 
“A” : “A”-imaging. 
“B” : “B”-imaging. 
LDL: low-density lipoprotein. Ox-LDL: oxidized low-density lipoprotein.   VLDL: very low-density 
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lipoprotein. HDL: high-density lipoprotein. LPC: lysophosphatidylcholine. PC: phosphatidylcholine. 
TG: triglyceride. Apo: apolipoprotein. MMP: matrix metalloproteinase. Chole: cholesteryl.  7-Keto chol: 
7-ketocholesterol.  
B: blue. Br: brown. G: green. Go: gold. LB: light blue. LY: light yellow. O: orange. P: purple. R: red. RBr: 
reddish brown. SB: sky blue. V: violet. W: white. Y: yellow.  - : no significant fluorescence. 
Underlined colors are characteristic for the corresponding substances. 
Table 1. Fluorescence Color of the Major Substances That Comprising Atherosclerotic 
Plaques 
b. Autofluorescence at “B”-imaging 
Collagen I and IV exhibit green autofluorescence whereas collagen III and V not. Calcium 
phosphate, ceramide and β-carotene exhibit yellow, yellow and orange autofluorescence, 
respectively. Other major subtances comprising atherosclerotic plaques do not exhibit auto-
fluorescence (Table 1).  
c. Color fluorescence of major substances that comprising atherosclerotic plaques evoked by 
markers 
Evans blue dye (EB) has been clinically used for intravascular imaging41-43, and its beneficial 
effects proved44.  
Oxidized low-density lipoprotein (ox-LDL) does not show autofluorescence, but presents a 
violet and a reddish brown fluorescence in the presence of EB by “A”- and “B”-imaging, 
respectively (Figure 4). This combination of fluorescent colors is not exhibited by any other 
major substances in the atherosclerotic plaques, indicating that this combination of 
fluorescent colors is due to ox-LDL (Table 1). 
TB has been clinically applied for treatment of Tripanosoma parasitemia many years ago45, 46. 
Although LPC and TB do not exhibit autofluorescence independently, a red fluorescence is 
evoked at both “A”- and “B”-imaging when they are mixed together. PC exhibits a pink and 
an orange fluorescence by “A”- and “B”-imaging, respectively38 (Figure 4).    
Nile blue dye (NB), which has been used as a electromechanical biosensor of DNA47. 
Apolipoprotein B-100 (apo B-100) exhibits no fluorescence at “A”-imaging but exhibits a 
golden fluorescence in the presence of NB at “B”-imaging (Figure 4, Table 1). 
In the presence of a mixture of homidium chloride (Ho) and TB, ox-LDL and LDL exhibit a 
golden fluorescence whereas LPC and apo B-100 a red fluorescence at “B”-imaging (Table 1). 
Since not exhibited by other major substances comprising atherosclerotic plaques, these 
fluorescent colors can be used for identification of the substances mentioned above. 
4. Near-infrared fluorescence (NIRF) of major substances that comprising 
atherosclerotic plaques 
Cholesterol, cholesteryl esters and calcium phosphate (Ca) individually do not exhibit NIRF 
but exhibit NIRF in the presence of β-carotene which is known to coexists with lipids in the 
vascular wall. The other substances that are contained in atherosclerotic plaques did not37 
(Figure 5; Table 2). 
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EB: Evans blue. TB: Trypan blue. NB: Nile blue. Ho+TB: Homidium chloride and Trypan blue.  
Fig. 4. Fluorescent Colors of Major Lipid Components Evoked by Biocompartible Markers 
Examined by Microscopy  
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Images before (upper panels) and after mixing with β-carotene (lower panels); From A to D: collagen I, 
free cholesterol, cholesteryl oleate, calcium phosphate, respectively; From A-1 to D-1: corresponding 
NIRFM images evoked after mixing with β-carotene (10-5M). Horizontal bar in each panel: 100μm. Cited 
from Ref. 37, with permission. 
Fig. 5. Near-infrared Fluorescent Microscopy (NIRFM) Images of Collagen I, Cholesterol, 
Choresteryl Oleate and Calcium Phosphate. 
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Table 2. Near-infrared Fluorescence (NIRF) of the Major Substances That Comprising 
Atherosclerotic Plaques 
5. Color fluorescent angioscopy of excised human coronary plaques  
a. Detection of vulnerable coronary plaques based on collagen subtype imaging 
Excised human coronary plaques exhibit blue, green, white-to-light blue, or yellow-to-
orange fluorescence. Fluorescent microscopic studies revealed that collagen subtypes, 
cholesterol, cholesteryl esters, calcium and β-carotene determine the fluorescent color of the 
plaques36. Histological examinations revealed abundant CFs without lipids in blue plaques; 
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CFs and lipids in green plaques; meager CFs and abundant lipids in white-to-light blue 
plaques; and the absence of CFs and deposition of lipids, calcium and macrophage foam 
cells in the thin fibrous cap in yellow-to-orange plaques, indicating that the yellow-to-
orange plaques were most vulnerable36 (Figures 6, 7).  
 
 
 
 
 
From A to D: conventional angioscopic images of coronary plaques. From A-1 to D-1: corresponding 
CFA images using “A” imaging. From A-2 to D-2: corresponding CFM scanned images using “A” 
imaging. Horizontal bar:100μm. A: a white plaque observed during conventional angioscopy (arrow) 
exhibited blue fluorescence by CFA (arrow in A-1) and CFM scan (A-2). B: a yellow plaque observed 
during conventional angioscopy (arrow) exhibited green fluorescence seen during CFA (arrow in B-1) 
and CFM scan (arrow in b-2).  C: a yellow plaque observed during conventional angioscopy (arrow) 
exhibited white-to-light blue fluorescence seen during CFA (C-1) and deposition of yellow substances in 
the white-to-light blue area (arrow in C-2). D: a yellow plaque observed during conventional 
angioscopy (arrow) exhibited yellow fluorescence observed during CFA (D-2) and deposition of orange 
(white arrowhead), white (white arrow) and blue (yellow arrow) substances in the area of no 
fluorescence by CFM scanning. Cited from Ref. 36, with permission. 
Fig. 6. Relationships between Images of Coronary Plaques Produced by Conventional 
Angioscopy, Color Fluorescent Angioscopy (CFA) and Color Fluorescent Microscopy (CFM) 
Scanning    
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From A-3 to D-3: microscopic images after Oil-red O and methylene blue staining obtained from the 
same plaques in A, B, C and D as shown in Figure. 6, respectively. Red: lipids. Black: calcium. LC: lipid 
core. Horizontal bar: 100μm. From A-4 to D-4: CFs stained by silver staining. No normal CFs in D-4. 
Arrow in D-4: plaque debris. Horizontal bar: 20μm. From A-5 to D-5: images of ceramide in    
macrophage foam cells obtained by “B” imaging of CFM after Ziel-Neelsen staining. Orange 
fluorescence (arrows): ceramide. Arrowhead in C-5: residual CFs. Horizontal bar: 20μm. A-3: a plaque 
without lipids, with abundant normal CFs (A-4) and without macrophage foam cells (A-5). B-3: a 
plaque with lipids, with thick CFs (B-4) but without macrophage foam cells (b-5).  C-3: a plaque with 
lipid deposition and cavity formation, meager CFs (C-4) and disseminated macrophage foam cells 
(arrow inC-5). D-3: a plaque with a thin fibrous cap with lipids and calcium (arrow in D-3), without CFs 
(D-4) and with multiple macrophage foam cells (arrows inD-5). Cited from Ref. 36, with permission.  
Fig. 7. Lipids, Calcium Compounds, Collagen Fibers (CFs), and Macrophage Foam Cells in 
the Same Plaques as Those Shown in Figure. 6.  
b. Oxidized low-density lipoprotein (Ox-LDL) imaging 
After the administration of EB in an ex-vivo study, not only the yellow plaques but also the 
white plaques studied by conventional angioscopy frequently presented a violet 
fluorescence by “A”-imaging and a reddish brown fluorescence by “B” imaging, indicating 
the existence of ox-LDL (Figure 8). The distribution of this fluorescence appeared in a patchy 
or diffuse manner. There was a tendency for this fluorescent color to appear more frequently 
in yellow plaques rather than the white plaques classified by conventional angioscopy36. By 
scanning microscopy, a violet and a reddish brown fluorescence distributed diffusely or in 
web-like configuration, indicating plaque to plaque differences in deposition pattern of ox-
LDL36.  
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A: a white plaque imaged by conventional angioscopy. Arrow: the portion observed by CFA.  B: “A”-
image of the same plaque before administration of EB. The plaque showed green autofluorescence, 
indicating existence of collagens-I and/or -IV (Table 1). B-1: CFA image after administration of EB. The 
plaque showed diffuse and violet fluorescence. C: “B”-image of the same plaque, showing green 
autofluorescence. C-1: “B”-image after administration of EB, showing reddish brown fluorescence. This 
combination of EB-evoked fluorescent color indicates the existence of ox-LDL. Cited from Ref. 36, with 
permission. 
Blue fluorescence (arrowhead in A-1) and green fluorescence(arrowhead in B-1) indicate collagen I 
and/or IV.  
Fig. 8. Ox-LDL in An Excised Coronary Plaque Imaged by Color Fluorescent Angioscopy 
(CFA)  
c. Lysophosphatidylcholine (LPC) imaging 
The red fluorescence of LPC was investigated by color fluorescent angioscopy in the excised 
human coronary plaques. This fluorescent color both at “A”-and “B”-imaging was detected 
frequently by color fluorescent angioscopy in both white and yellow plaques that were 
classified by conventional angioscopy using white light (Figure 9). As in case of ox-LDL, this 
fluorescent color was found to be distributed in web-like or diffuse configuration by color 
fluorescent microscopic scanning38 (Figure 10). 
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A: a yellow plaque imaged by conventional angioscopy. Arrow: the portion observed by CFA.  B and C: 
CFA images of the same plaque before administration of TB. The plaque showed green and blue 
fluorescence in mosaic pattern by “A” imaging, and green and yellow fluorescence in mosaic pattern by 
“B” imaging, indicating the  co-existence of collagen I and/or IV and lipids. B-1 and C-1: CFA images 
after administration of TB. The plaque showed red fluorescence by both” A”-and “B”-imaging, 
indicating the existence of LPC. Cited from Ref. 38, with permission. 
Fig. 9. Lysophosphatidylcholine (LPC) in A Coronary Plaque Imaged by Color Fluorescent 
Angioscopy (CFA) 
 
A: yellow plaque imaged by conventional angioscopy.  B and B-1: CFM  scanned luminal surface of the 
same plaque after the application of TB, showing wed-like distribution of red fluorescence and therefore  
web-like deposition of LPC (arrows).  Horizontal bar in B-1: 100μm. This bar is also applicable to B. 
Cited from Ref. 38, with permission. 
Fig. 10. Distribution Patterns of Lysophosphatidylcholine (LPC) in A Coronary Plaque by 
Color Fluorescent Microscopy (CFM) Scanning  
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d. Apo B-100 imaging 
In the presence of NB, golden fluorescence, diffuse, spotty or web-like configuration, was 
observed in excised human coronary arteries by “B”-imaging, indicating deposition of apo 
B-100. However, the relationship between deposition patterns of this substance and plaque 
structure by histology is not clarified. 
e. Triglyceride (TG) imaging 
Imaging of TG, a major component of the core of ox-LDL, by CFA is yet not successful 
because of a lack in appropriate biocompartible markers.   
f. HDL and LDL imaging 
Selective imaging of HDL and LDL by fluorescent angioscopy is yet not successful as in case 
of TG.    
 
A: Yellow plaque imaged by conventional angioscopy. Arrow: the  portion observed by CFA  A-1 and 
A-2: CFA images of the same plaque before and after administration of Ho and TB solution (Ho+TB), 
respectively. The plaque showed greenish yellow autofluorescence before (arrow in A-1) and red 
(arrowheads in A-2) and golden fluorescence (arrow in A-2) in a mosaic pattern after the administration 
of Ho and TB, indicating co-existence of ox-LDL and/or  LDL, and LPC and /or apo B-100.  B: Yellow 
plaque by conventional angioscopy (arrow). B-1 and B-2: CFA images before and after administration of 
Ho and TB solution (Ho+TB), respectively. The plaque showed yellow autofluorescence (arrow in B-1) 
before and red fluorescence (arrow in  B-2) after the administration of Ho and TB solution, indicating 
deposition of LPC and/or apo B-100. 
Cited from Ref. 39, with permission. 
Fig. 11. Oxidized Low-density Lipoprotein (Ox-LDL), LDL, Lysophosphatidylcholine (LPC), 
and Apolipoprotein (ApoB) in Coronary Plaques Imaged by Color Fluorescent Angioscopy 
(CFA)  
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g. Simultaneous imaging of oxidized low-density lipoprotein (Ox-LDL), low-density lipoprotein 
(LDL), lysophosphatidylcholine (LPC) and apolipoprotein B-100 (apo B-100) 
By “B”-imaging, ox-LDL and LDL (group A) exhibit golden fluorescence, while LPC and 
apo B-100 (group B) exhibit red fluorescence. By color fluorescent angioscopy, coronary 
plaques frequently exhibited red and golden fluorescence in a mosaic pattern, indicating co-
deposition of A and B. Red fluorescence was also observed in a small number of plaques, 
indicating solitary deposition of B39 (Figure 11).  
 
From A to D: the images of coronary plaques by conventional angioscopy.  
From A-1 to D-1: corresponding NIRFA images of the same plaques. From A-2 to D-2 : corresponding 
NIRFM scanned images of the cut wall surface of the same specimens . From A-3 to D-3: corresponding 
histological images after staining with Oil Red-O and methylene blue. Red and black portions indicate 
lipids and calcium, respectively. Horizontal bar at the left upper corner of each panel: 100 μm. 
A: a white plaque. From B to D: yellow plaques. A-1 and B-1: homogenous type. Arrows: homogenous 
NIRF; C-1: doughnut-shaped type. Arrow: NIRF absent portion surrounded by strong NIRF region; D-1: 
spotty type. Arrow: spots. A-2 and B-2: homogenous NIRF (arrows); C-2 : necrotic core lacking NIRF 
(arrow) surrounded by strong NIRF region; D-2: fibrous cap with strong NIRF spots (arrow). A-3: 
homogenous deposition of lipids deep in the plaque (arrow); B-3: lipid deposition in entire plaque. C-3: 
lipid-deposited fibrous cap with a necrotic core (NC) belowD-3: calcium particles distributed within a 
lipid-laden fibrous cap. Red: lipids. Black: calcium compounds (arrow).   
Horizontal bar: 100μm. Cited from Ref. 37, with permission. 
Fig. 12. Relationships Among Conventional Angioscopic, Near-infrared Fluorescent 
Angioscopic (NIRFA), and Near-infrared Fluorescent Microscopic (NIRFM) Scanned Images 
and Histological Changes in Excised Human Coronary Plaques. 
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6. Near-infrared fluorescent angioscopy of excised human coronary plaques 
a. Cholesterol (C) and cholesteryl ester (CE) imaging 
In an ex-vivo study, excised human coronary plaques were classified as those with NIRF 
and those without. The former plaques were classified into homogenous, doughnut-shaped 
and spotty types37.  
Histological examinations revealed that these image patterns were determined by the 
differences in the locations of cholesterol, cholesteryl esters and Ca, and that those deposited 
within 700μm in depth from plaque surface were imaged by NIRFA37 (Figure 12).  
7. Clinical application of fluorescent angioscopy 
a. Oxidized low-density lipoprotein (ox-LDL) 
In our catheterization laboratory, CFA was performed during routine coronary angioscopy 
in patients with coronary artery disease.  
After selective injection of the EB solution into the coronary artery, not only the plaques but 
also the apparently normal coronary segments frequently exhibited a reddish brown 
fluorescence by “B”-imaging, indicating the existence of ox-LDL36 (Figure 13).  
 
Reddish brown fluorescence observed in a non-stenotic proximal segment of the left anterior 
descending coronary artery after the intracoronary injection of EB in a patient with stable angina 
pectoris. 
 A: an angiogram of the left coronary artery. Arrows a to b: the proximal segment observed by CFA. The 
wall of the segment was uneven but significant stenosis was not found. 
From .B to E: CFA images of the same segment obtained after injecting EB, by advancing the angioscope 
distally from a to b of panel A.  Reddish brown portions indicate ox-LDL. The luminal surface was  
uneven, indicating early stage of atherosclerosis. Cited from Ref. 36, with permission. 
Fig. 13. Ox-LDL Imaged by “B”-imaging of Color Fluorescent Angioscopy (CFA) in the 
Coronary Artery in A Patient with Angina Pectoris 
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b) Cholesterol and cholesteryl esters 
The present authors examined coronary plaques by NIRFA during coronary angiography in 
25 patients with coronary artery disease. Figure 14 shows a yellow plaque by conventional 
angioscopy. This plaque exhibited homogenous NIRF, indicating homogenous deposition of 
cholesterol and/ or choresteryl esters. Homogenous, doughnut-shaped or spotty NIRFA 
images were also observed in patients37. 
 
 
From A to C: angiogram, conventional angioscopic image and NIRFA image of a plaque in the proximal 
segment of the left anterior descending coronary artery (arrow in A). The yellow plaque (arrow in B) 
presented a homogenous type NIRF image (B-1). Arrowhead: guide wire. 
Cited from Ref. 37, with permission. 
Fig. 14. Near-infrared Fluorescent Angioscopy (NIRFA) Study in a 61-year-old Male with 
Stable Angina.  
8. Discussion 
The use of an antibody of individual components that comprising vessel wall is a more 
specific indicator for their imaging in-vivo. However, there are many limitations to its 
clinical application. Therefore, the use of a low molecular weight substance that selectively 
binds to individual components and presents specific fluorescence color is another option 
that can be used for the imaging of individual lipid components.  
In the present study, low molecular weight dyes with, EB, TB, NB, Ho+TB were found to 
evoke fluorescence specific to ox-LDL and its components except TG and Schiff base. Thus, 
visualization of ox-LDL and its major components in a given plaque was achieved, enabling 
analysis of the differences in their deposition patterns in human coronary plaques. The 
mechanisms by which these dyes evoked fluorescence are not known. One possibility is that 
dyes became conjugated to the target substances to form an adduct to provoke a fluorescent 
color specific to individual substances.  
Ox-LDL, which plays an important role in the initiation, progression and destabilization of 
atherosclerotic plaques, became visible for the first time by CFA in patients. Furthermore, 
the substances that comprising ox-LDL became visible by CFA or NIRFA in excised human 
coronary arteries. 
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However, CFA and NIRFA have been limited to collagen subtypes, ox-LDL, cholesterol and 
cholesteryl esters in clinical situations. Imaging of other substances by CFA or NIRFA in 
patients is yet not performed because clinical applicability of biocompartible markers other 
than EB is not established.  
Fluorescent angioscopy faced some shortcomings; (1) The visualization by CFA is limited only 
to the substances deposited within 200μm from the vascular luminal surface and by NIRFA 
within 700 μm (Table 3). Therefore deposits in the deeper layers can not be analyzed by this 
system of CFA and NIRFA.（2) Differing in function to antibodies, biomarkers employed in 
CFA do not selectively bind to the target substance, and therefore, there may be other 
unknown substances which exhibit the same fluorescent color in the presence of the markers 
used. (3) Because a lens is used, the pictures obtained by CFA and NIRFA are fish-eye images 
and therefore quantitative assessment of the target substance is difficult (Table 3).     
 
CFA: color fluorescent angioscopy. NIRFA: near-infrared fluorescent angioscopy. 
Table 3. Advantages and Disadvantages of Angioscopy 
At present, imaging by fluorescent angioscopy is limited to several substances that comprise 
coronary plaques. By selecting adequate biomarkers, the substances other than those 
mentioned above may become visible. 
Fluorescent angioscopy was established only recently and therefore its clinical application is 
limited to a few laboratories. As in spectroscopy, this technique will become prevalent when 
clinically applicable biomarkers for the substances comprising atherosclerotic lesions 
become complete. 
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9. Conclusion 
LDL has cortex and core. The cortex is composed of PC, free cholesterol  and apo B-100, and 
the core is composed of TG and cholesteryl esters. Ox-LDL is derived from LDL by 
oxidation of its component PC into LPC and apo B-100 into Shiff base, and plays an 
important role in the initiation, progression and destabilization of atherosclerotic plaques by 
inducing the proliferation and elongation of survival of macrophages.  
We succeeded in molecular imaging of ox-LDL not only in the excised human coronary 
plaques but also in coronary arteries in patients in-vivo by CFA using EB as a biomarker. Also, 
LPC, apo B-100, free cholesterol, and cholesteryl esters in human coronary plaques became 
visible by either CFA or NIRFA. These imaging techniques will give us much information 
which is otherwise not obtainable on the mechanisms of atherosclerosis in clinical situation.  
10. References 
[1] Ge J, Baumgart D, Hauda M, et al. Role of intravascular ultrasound imaging in 
identifying vulnerable plaques. Herz. 1999; 24: 32-41. 
[2] Jang IK, Tearney GJ, MacNeil B, et al. In vivo characterization of coronary atherosclerotic 
plaque by use of optical coherence tomography. Circulation. 2005; 111: 1551-1555.  
[3] Uchida Y. Coronary Angioscopy. Futura Publishing Co, NY, 2001: 11-81 
[4] Uchida Y, Prediction of acute coronary syndromes by percutaneous angioscopy in 
patients with stable angina. Am Heart J 1995, 130: 195-203.  
[5] Thieme T, Wernecke KD, Meyer R, et al. Angioscopic evaluation of atherosclerotic 
plaques: validation by histomorphologic analysis and association with stable and 
unstable coronary syndromes. J Am Coll Cardiol 1996; 28: 1-6. 
[6] Uchida Y, Uchida Y, Hiruta N. Histological characteristics of glistening yellow coronary 
plaques seen on angioscopy: with special reference to vulnerable plaques. Circ J. 
2011; 75: 1913-1919.  
[7] Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. 
Autoimmun Rev. 2008; 7: 558-566. 
[8] Chen JH, Riazzy, Smith EM, Proud CG, Steinbrecher UP, Duronio V. Oxidized LDL-
mediated macrophage survival involves elongation of factor-2 kinase. Arterioscler 
Thromb Vasc Biol 2009; 29: 92-98. 
[9] Katsuda S, Okada Y, Minamoto T, Matsui Y, Nakanishi I. Collagens in human 
atherosclerosis: Immunohistochemical analysis using collagen type-specific 
antibodies. Atheroscler Thromb. 1992; 12:494-502. 
[10] Murata K, Motoyama T. Collagen species in various sized arteries, their changes with 
intimal proliferation. Artery. 1990; 17: 96-106. 
[11] Murata K, Kotake C, Motoyama T: Collagen species in human aorta: with special 
reference to basement membrane-associated collagens in the intima and media and 
their alteration with atherosclerosis. Artery. 1987; 14: 229-247. 
[12] Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce 
breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-
metalloproteinases and implication for plaque rupture. Circulation 1995; 92: 1565-1569. 
[13] Takano T, Itabe H, Mori M, et al. Molecular pathology in atherosclerosis: the 
mechanisms by which cholesteryl ester accumulates in atherosclerotic aorta. 
Yakugaku Zasshi. 2008; 128: 1383-1401. 
www.intechopen.com
 Molecular Imaging of Atherosclerotic Coronary Plaques by Fluorescent Angioscopy 
 
267 
[14]  Li W, Yuan XM, Olsson AG, Brunk UT. Uptake of oxidized LDL by macrophages 
results in partial lysosomal enzyme inactivation and relocation. Arterioscler 
Thromb Vasc Biol. 1998; 18: 177-184. 
[15] Grandl M, Bared SM, Liebisch G, Werner T, Barlage S, Schmitz G. E-LDL and ox-LDL 
differentially regulate ceramide and cholesterol raft microdomains in human 
macrophages. Cytometry A. 2006; 69: 189-191. 
[16] Tardif JC. Emerging high-density lipoprotein infusion therapies: fulfilling the promise 
of epidemiology? J Clin Lipidol. 2010; 4: 399-404. 
[17] Negi S, Ballantyne CM. Insights from recent meta-analysis: role of high-density 
lipoprotein cholesterol in reducing cardiovascular events and rates of 
atherosclerotic disease progression. J Clin Lipidol. 2010; 4: 365-370. 
[18] Vilani SS, Nambi V. The role of lipoprotein-associated phospholipase A2 as a marker of 
atherosclerosis. Curr Atheroscler Rep 2007; 9: 97-103. 
[19] Erdogan A, Schaefer MB, Kulmann CR, Most A, Hartmann M, Mayer K, Renner FC, 
Schaefer C, Abdallah Y, Hoelschermann H, Schaefer CA. Activation of Ca2+-
induced potassium channels is involved in lysophosphatidylcholine-induced 
monocyte adhesion to endothelial cells. Atherosclerosis. 2007; 190: 100-105. 
[20] Matsubara M, Hasegawa K. Benipine, a dihydopyridine-calcium channel blocker, 
prevents lysophosphatidylcholine-induced injury and reactive oxygen species 
production in human aortic endothelial cells. Atherosclerosis. 2005; 178: 57-66. 
[21] Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphadidylcholine (LPC) in 
atherosclerosis. Curr Med Chem. 2007; 14: 3209-3220. 
[22] Stollenberk MM, Svensson O, Schiopu A, Jansson B, Arnebrant T, Fredrikson GN. A 
desorption of low-density lipoprotein, its oxidation, and subsequent binding of 
specific recombinant antibodies: an in situ ellipsometric study. Biochim Acta. 2011; 
1810: 211-217. 
[23] Kanani FH, Alam JM. Apolipoprotein B in type 2 diabetes—a cross sectional study in a 
tertiary care set-up. J Pak Med Assoc. 2010; 60: 653-656. 
[24] Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Apolipoprotein B, 
non-HDL cholesterol and LDL cholesterol for identifying individuals at increased 
cardiovascular risk. J Intern Med. 2010; 68: 567-677. 
[25] Enkhmaa B, Annurad E, Zhang Z, Pearson TA, Berglund L. Usefulness of apolipoprotein 
B/ apolipoprotein A-1 ration to predict coronary artery disease independent of the 
metabolic syndrome in African Americans. Am J Cardiol. 20210; 106: 1264-1269. 
[26] Kappelle PJ, Gansevoort RT, Hillege JL, Wolffenbultel BH, Dullaart RP. Apolipoprotein 
B/A-1 and total cholesterol/high-density lipoprotein cholesterol rations both 
predict cardiovascular events in the general population independently of nonlipid 
risk factors, albuminuria and C-reactive protein. J Interm Med. 2011; 269: 232-242 
[27] Lee YH, Choi SH, Lee KW, Kim DJ. Apolipoprotein B/A1 ratio is associated with free 
androgen index and visceral adiposity and may be an indicator of metabolic 
syndrome in male children and adolescence. Clin Endoclinol. 2011; 74: 579-588  
[28] Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams 
LA. Achievement of lipid targets with combination of rosuvastatin and fenofibric 
acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2011; 25: 47-57  
[29] Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and 
carotid atherosclerosis: a systematic review of the epidemiological studies. 
Atherosclerosis. 2009; 203: 331-345. 
[30] Gandotra P, Miller M. The role of triglycerides in cardiovascular risk. Curr Cardiol Rep. 
2008; 10: 505-511.  
www.intechopen.com
 Molecular Imaging 
 
268 
[31] Colley CS, Kazarian SG, Weinberg PD, Lever MJ. Spectroscopic imaging of arteries and 
atherosclerotic plaques. Biopolymers. 2004; 74: 328-335. 
[32] Krisko A, Stjepanoic G, Pifat G, Ruysechaert JM, Goormaghtigh E. Detection of 
apolipoprotein B 100 early conformatical changes during oxidation. Biochim 
Biophys Acta. 2007; 1768: 2923-2930. 
[33] Garg S, Serruys PW, van der Ent M, Schultz C, Mastik F, van Soest G, van der Steen AF, 
Wilder JE, Regar E. First use in patients of a combined infra-red spectroscopy and 
intra-vascular ultrasound catheter to identify composition and structure of 
coronary plaque. Eurointervention. 2010; 5: 755-756. 
[34] Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang BY, Mehta JL, Beller GA, 
Glover DK, Meyer CH. Molecular imaging of atherosclerotic plaques targeted to 
oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ 
Cardiovasc Imaging. 2010; 3: 464-472. 
[35] Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, Wiltztum JL, 
Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging 
atherosclerotic lesions with magnetic resonance using antibodies that recognize 
oxidation-specific epitopes. Circulation. 2008; 117: 3206-3215. 
[36] Uchida Y, Uchida Y, Kawai S, Kanamaru R, Sugiyama Y, Tomaru T, Maezawa Y, 
Kameda N. Detection of vulnerable coronary plaques by color fluorescent 
angioscopy. JACC Cardiovasc Imaging. 2010; 3: 398-408. 
[37] Uchida Y, Uchida Y, Sugiyama Y, Kanai M, Sakurai T, Shirai S. Two-dimensional 
visualization of cholesterol and cholesteryl esters within human coronary plaques 
by near-infrared fluorescence angioscopy. Clinical Cardiology. 2010; 33: 322-325. 
[38] Uchida Y, Uchida Y, Kawai S, Kanamaru R, Kameda N. Imaging of 
lysophosphatidylcholine in human coronary plaques by color fluorescence 
angioscopy. Int Heart J. 2010; 51: 129-133. 
[39] Uchida Y, Uchida Y, Kameda N. Visualization of lipid components in human coronary 
plaques using color fluorescence angioscopy. Circ J. 2010; 74: 2181-2186. 
[40] Uchida Y. Recent advances in coronary angioscopy. J Cardiol. 2011; 57: 18-30. 
[41] Uchida Y. Angioscopy system. In Coronary angioscopy, Uchida Y (ed), Futura 
Publishing INC, Armonk, NY, 2001; 11-103.  
[42] Uchida Y, Nakamura F, Tomaru T. Observation of atherosclerotic lesions by an 
intravascular microscope in patients with arteriosclerosis obliterance. Am Heart J. 
1995; 130: 1114-1117. 
[43] Uchida Y, Uchida Y, Sakurai T, Kanai M, Shirai S, Morita T.Characterization of coronary 
fibrin thrombus in patients with acute coronary syndrome using dye-staining 
angioscopy. ArteriosclerThromb Vasc Biol. 2011; 31: 1452-1460. 
[44] Uchida Y, Uchida H. Therapeutic tool for vascular disease. United States Patent. 
US7025981 B2, 2006. 
[45] Ralph P, Nakoinz I. Environmental and chemical dissociation of antibody-dependent 
phagocytosis from lysis mediated by macrophages: stimulation of lysis by 
sulfhydryl-blocking and elastase-inhibitory agents and depression by trypan blue 
and trypsin. Cell Immunol 1980; 50: 94-105. 
[46] Brooks BO, Reed ND. The effect of trypan blue on the early control of Trypanosoma 
musculi parasitemia in mice. J Reticuloendothel Soc. 1979; 25: 325-328. 
[47] Chen ZW, Balamurungan A, Chen SM. Detection of DNA by using bio-conducting 
polymer-Nile blue composite electrode; Nile blue as an indicator. 
Bioelectrochemistry. 2009; 75: 13-18. 
www.intechopen.com
Molecular Imaging
Edited by Prof. Bernhard Schaller
ISBN 978-953-51-0359-2
Hard cover, 390 pages
Publisher InTech
Published online 16, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The present book gives an exceptional overview of molecular imaging. Practical approach represents the red
thread through the whole book, covering at the same time detailed background information that goes very
deep into molecular as well as cellular level. Ideas how molecular imaging will develop in the near future
present a special delicacy. This should be of special interest as the contributors are members of leading
research groups from all over the world.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yasumi Uchida and Yuko Maezawa (2012). Molecular Imaging of Atherosclerotic Coronary Plaques by
Fluorescent Angioscopy, Molecular Imaging, Prof. Bernhard Schaller (Ed.), ISBN: 978-953-51-0359-2, InTech,
Available from: http://www.intechopen.com/books/molecular-imaging/molecular-imaging-of-coronary-plaques-
by-fluorescent-angioscopy
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
